Norges Bank’s Carisma Therapeutics CARM Stock Holding History

Norges Bank’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-62,795	Closed	-$996K	–	2218
2021 Q3	$996K	Buy	+62,795	New	+$3.01M	﹤0.01%	2146

Other funds holding CARM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Norges Bank's CARM Position: Q4 2021 in Review

Norges Bank sold out of Carisma Therapeutics (CARM) in Q4 2021, closing a stake of 62,795 shares — an estimated $996K sold.

Norges Bank first reported a position in CARM in Q3 2021 and held it in 1 quarter. The position peaked at $996K in Q3 2021. 93 funds tracked by Wall St. Rank hold CARM as of Q4 2021.

Norges Bank reported no remaining Carisma Therapeutics position as of Q4 2021 after selling out during the quarter.
Norges Bank sold 62,795 Carisma Therapeutics shares in Q4 2021, an estimated $996K.
Norges Bank first reported a position in Carisma Therapeutics in Q3 2021 and held it in 1 quarter.
Norges Bank's Carisma Therapeutics position peaked at $996K in Q3 2021.
93 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2021.

Based on Norges Bank's 13F filing for Q4 2021, filed 10 Feb 2022.